RxDoctor Payments Data

David Tukel, MD

Ophthalmology · Dearborn, MINPI 1922079995

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $71,225 of the $91,311 with a category attached, or 78.0%. Sun Pharmaceutical Industries Inc. accounts for 91.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $30,585 and has fallen 75.4% since, to $7,510 in 2024. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$91,311in general payments, 2019–2025

Across 190 payments — averaging $480.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$83K
  • Kala Pharmaceuticals, Inc.$7K
  • Alcon$585
  • Aerie Pharmaceuticals, Inc.$439
  • Novartis$107
  • AbbVie$51
  • plus $193 from 8 others

What the payments were for

  • Speaking & faculty fees$71,22578%
  • Travel & lodging$15,66317%
  • Food & beverage$4,4045%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,311 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$22,047
Medicare patients
103
Services billed
251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CequaCyclosporine26$17,640
ProlensaBromfenac Sodium18$9,795
Cyclosporine11$6,373
Latanoprost256$5,519
Bromfenac Sodium18$4,772
Timolol Maleate66$1,841
Ketorolac Tromethamine37$1,100
Brimonidine Tartrate44$625
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat16$343
ErythromycinErythromycin Base15$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sun Pharmaceutical Industries Inc.Cequa$83,098$17,64026 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$32$9,79518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →